No Data
Maxim Group Maintains Alzamend Neuro(ALZN.US) With Hold Rating
Alzamend Neuro (ALZN) Gets a Hold From Maxim Group
Express News | Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of Al001 to Take Place at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to Take Place at Massachusetts General Hospital
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Express News | EXCLUSIVE: Alzamend Neuro Tells Benzinga Co. Plans To Initiate The First Of Five Highly Anticipated Phase II Clinical Studies Of AL001, With The Study, In Healthy Human Subjects, Expected To Commence In Q2 2025
